Centaurus Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Centaurus Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-752	Closed	-$151K	–	743
2023 Q1	$151K	Buy	752 +11	+1%	+$2.31K	0.01%	744
2022 Q4	$176K	Buy	741 +18	+2%	+$3.84K	0.02%	643
2022 Q3	$145K	Buy	723 +23	+3%	+$4.39K	0.01%	705
2022 Q2	$102K	Hold	700	–	–	0.01%	800
2022 Q1	$114K	Hold	700	–	–	0.01%	829
2021 Q4	$119K	Hold	700	–	–	0.01%	839
2021 Q3	$132K	Hold	700	–	–	0.01%	771
2021 Q2	$119K	Buy	+700	New	+$103K	0.01%	811
2020 Q4	–	Sell	-720	Closed	-$105K	–	775
2020 Q3	$105K	Hold	720	–	–	0.01%	612
2020 Q2	$107K	Buy	+720	New	+$97.1K	0.02%	582
2018 Q3	–	Sell	-688	Closed	-$68K	–	582
2018 Q2	$68K	Buy	+688	New	+$68.2K	0.01%	834

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Centaurus Financial's ALNY Position: Q2 2023 in Review

Centaurus Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 752 shares — an estimated $151K sold.

Centaurus Financial first reported a position in ALNY in Q2 2018 and held it in 11 quarters. The position peaked at $176K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Centaurus Financial reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Centaurus Financial sold 752 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $151K.
Centaurus Financial first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Centaurus Financial's Alnylam Pharmaceuticals position peaked at $176K in Q4 2022.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Centaurus Financial's 13F filing for Q2 2023, filed 15 Aug 2023.